
|Videos|July 20, 2020
A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia
Author(s)Jeff Sharman, MD
Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.
Advertisement
Case: A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia
Initial presentation
- A 79-year-old man presented to a new medical oncologist for the first time complaining of vague intermitted abdominal pain, and progressive fatigue
- PMH:
- Hypertension, medically controlled
- MI, 8 years ago, on 81 mg aspirin
- CLL, diagnosed 7 years ago
- After a period of watchful waiting he began treatment with ibrutinib 420 mg PO qDay; symptoms improved and achieved stable disease, resolution of lymphadenopathy
- After 5 years of disease control on ibrutinib he complained of increasing fatigue and decreased appetite, on physical exam there was return of palpable lymphadenopathy; spleen was palpable ~4 cm below costal margin
- He was started on rituximab
- Currently after 6 months on rituximab monotherapy he presents to the clinic
- PE: palpable bilateral cervical and right-sided inguinal lymphadenopathy
Clinical workup
- Labs: WBC 55,000, lymphocyte 82%, ANC 3100/mm3, Hb 9.4 g/dL, plt 90 x 109/L, LDH 220 U/L, Beta-2-microglobulin 3.9 mg/L; creatinine clearance 31 mL/min
- FC CD 5+, CD19+, CD20+ monoclonal B-cell population
- FISH: CLL probe set tested, deletion 17p
- IgHV mutational status: unmutated
- Rai stage IV; ECOG PS 1
- Treatment of idelalisib 150 mg PO BID was added to rituximab
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































